Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06724926 · ClinicalTrials.gov registry record · Phase 1

Concurrent Azeliragon With Craniospinal Irradiation

A Phase 1 study of Solid Tumor and High Grade Glioma, sponsored by NYU Langone Health.

Recruiting
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT06724926: Recruiting Phase 1 study of Solid Tumor and High Grade Glioma, sponsored by NYU Langone Health.

NCT06724926 is a Phase 1 study of Solid Tumor and High Grade Glioma that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 32 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06724926, a Phase 1 study of Solid Tumor and High Grade Glioma, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

Single institution study to assess the safety of concurrent Azeliragon with craniospinal irradiation (CSI) in patients with leptomeningeal metastasis from solid tumor malignancies and high-grade gliomas.

Primary Outcome

DLTs assess using Common Terminology Criteria for Adverse Events (CTCAE) v 5.0.

Conditions Studied

Solid Tumor High Grade Glioma Leptomeningeal Metastasis

Interventions

  • DRUG Azeliragon
  • PROCEDURE CSI

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-02-18
Est. Completion 2031-01
Phase Phase 1
NYU Langone Health

1,164 total trials

What NCT06724926 shows while recruiting

NCT06724926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (86% lower).

The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Azeliragon is the first listed.

NCT06724926 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06724926 about?

NCT06724926 is a clinical study titled "Concurrent Azeliragon With Craniospinal Irradiation". Single institution study to assess the safety of concurrent Azeliragon with craniospinal irradiation (CSI) in patients with leptomeningeal metastasis from solid tumor malignancies and high-grade gliomas.

What is the current status of trial NCT06724926?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-02-18. Estimated completion is 2031-01.

What conditions does trial NCT06724926 study?

This clinical trial studies the following conditions: Solid Tumor, High Grade Glioma, Leptomeningeal Metastasis.

What interventions are being tested in trial NCT06724926?

The interventions under investigation include: Azeliragon (DRUG), CSI (PROCEDURE).

Who is sponsoring clinical trial NCT06724926?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06724926 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06724926's enrollment target sits among peer trials

32 153rd of 196 higher than 44 of 196 other Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06724926

Source: ClinicalTrials.gov NCT06724926, the US trial registry maintained by the National Library of Medicine. NCT06724926 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.